UFP Technologies (NASDAQ:UFPT) & Arch Therapeutics (OTCMKTS:ARTH) Head to Head Comparison

UFP Technologies (NASDAQ:UFPTGet Free Report) and Arch Therapeutics (OTCMKTS:ARTHGet Free Report) are both small-cap industrial products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Volatility & Risk

UFP Technologies has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 3.62, suggesting that its share price is 262% more volatile than the S&P 500.

Profitability

This table compares UFP Technologies and Arch Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
UFP Technologies 11.75% 17.40% 12.04%
Arch Therapeutics -6,460.51% N/A -489.95%

Insider & Institutional Ownership

87.3% of UFP Technologies shares are owned by institutional investors. Comparatively, 6.9% of Arch Therapeutics shares are owned by institutional investors. 6.2% of UFP Technologies shares are owned by insiders. Comparatively, 4.5% of Arch Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares UFP Technologies and Arch Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UFP Technologies $400.07 million 4.95 $44.92 million $6.22 41.49
Arch Therapeutics $80,000.00 87.73 -$6.98 million N/A N/A

UFP Technologies has higher revenue and earnings than Arch Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for UFP Technologies and Arch Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UFP Technologies 0 1 1 0 2.50
Arch Therapeutics 0 0 0 0 N/A

UFP Technologies presently has a consensus target price of $238.50, indicating a potential downside of 7.59%. Given UFP Technologies’ higher probable upside, equities research analysts clearly believe UFP Technologies is more favorable than Arch Therapeutics.

Summary

UFP Technologies beats Arch Therapeutics on 9 of the 11 factors compared between the two stocks.

About UFP Technologies

(Get Free Report)

UFP Technologies, Inc. designs and manufactures solutions for medical devices, sterile packaging, and other highly engineered custom products. The company offers protective drapes for robotic surgery, single patient use surfaces, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, biopharma drug manufacturing, and coils for catheters; and molded components for applications in acoustic insulation, interior trim, load floors, sunshades, SUV cargo cover handles, driveshaft damping, engine and manifold covers, quarter panels, and wheel liners. It also provides molded composites for commercial aviation and military gear for use in backpack components, knee and elbow pads, eyewear, and helmets; and reusable cases and custom for applications in military ballistics panels, virtual training systems, drones, communications equipment, and rugged portable computers. In addition, the company provides engineered products and components to customers in the automotive, aerospace and defense, and industrial markets for applications in military uniform and gear components, automotive interior trim, air filtration, and protective cases and inserts. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

About Arch Therapeutics

(Get Free Report)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive News & Ratings for UFP Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UFP Technologies and related companies with MarketBeat.com's FREE daily email newsletter.